Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far

This article was originally published in The Pink Sheet Daily

Executive Summary

All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.


Related Content

Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer Essential Health Is Staying Put And Has A Focused Strategy For Growth
Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
Lessons From The First Biosimilar MAb Launch In Europe


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts